First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN-Reference-Cited by-同舟云学术

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

Published:2023-04 Issue:4 Volume:4 Page:100471
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Hayashi Hidetoshi^ORCID,Teraoka Shunsuke,Goto Yasushi,Kumagai Toru,Nishio Makoto,Sugawara Shunichi,Oizumi Satoshi,Matsumura Masakazu,Okura Masayuki,Peltz Gerson,Kato Terufumi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Systemic treatment patterns with advanced or recurrent non-small cell lung cancer in Japan: a retrospective hospital administrative database study;Wang;Clin Ther,2017

2. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

3. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer;Solomon;J Thorac Oncol,2009

4. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2020

5. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial;Hida;Lancet,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

2. Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study;JTO Clinical and Research Reports;2024-03

3. Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor;Current Treatment Options in Oncology;2023-11-08

4. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11